Cancer Statistics, 2021.
Reads0
Chats0
TLDR
In the United States, the cancer death rate has dropped continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment as mentioned in this paper.Abstract:
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.read more
Citations
More filters
Journal ArticleDOI
A light and hypoxia-activated nanodrug for cascade photodynamic-chemo cancer therapy
Yin Zhong,Si Huang,Chujie Zheng,Jinsheng Huang,Bo Li,Shisong Han,Hong Xiao,Yong Wang,Xintao Shuai +8 more
TL;DR: In this article, a pH-responsive block polymer consisting of polyethylene glycol (mPEG) and poly(asparagyl diisopropylethylenediamine-co-phenylalanine) (P(DIP)-co-Phe)) is synthesized for drug delivery.
Journal ArticleDOI
Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2–4 cm; emerging data and future perspectives
TL;DR: A systematic literature review as mentioned in this paper evaluated the oncologic and obstetric outcomes for women that underwent neoadjuvant chemotherapy (NACT) before fertility sparing surgery for tumors 2-4 cm.
Journal ArticleDOI
Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer
TL;DR: In this paper , the authors performed transcriptome analysis in HR-proficient human ovarian cancer cells and tested drug effects in established immunocompetent mouse ovarian cancer models, and concluded that panobinostat in combination with olaparib targets ovarian tumors through both direct cytotoxic and indirect immune-modulating effects.
Journal ArticleDOI
Cryptolepine Targets TOP2A and Inhibits Tumor Cell Proliferation in Breast Cancer Cells - An in vitro and in silico Study.
TL;DR: Cumulatively, this study signifies that TOP2A promotes breast cancer progression, and targetingTOP2A in combination with other therapeutic agents will significantly enhance the response of BC patients to therapy and reduce the development of chemoresistance.
Journal ArticleDOI
KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis
Tanja Limberger,Michaela Schlederer,Karolina Trachtova,Ines Garces de los Fayos Alonso,Jiaye Yang,Sandra Högler,Christina Sternberg,Vojtech Bystry,Jan Oppelt,Boris Tichy,Margit Schmeidl,Petra Kodajova,Anton Jäger,Heidi A. Neubauer,Monika Oberhuber,B. Schmalzbauer,Šárka Pospíšilová,Helmut Dolznig,Wolfgang Wadsak,Zoran Culig,Suzanne D. Turner,Gerda Egger,Sabine Lagger,Lukas Kenner +23 more
TL;DR: In this paper , the effect of truncation mutations of the histone lysine N-methyltransferase (KMT2C) was investigated in prostate cancer and the effects of these mutations were elucidated by deleting the C-terminal catalytic core motif of KMT2c.
References
More filters
Journal ArticleDOI
Cancer statistics, 2019.
TL;DR: The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak.
Journal ArticleDOI
Cancer statistics, 2016
TL;DR: Overall cancer incidence trends are stable in women, but declining by 3.1% per year in men, much of which is because of recent rapid declines in prostate cancer diagnoses, and brain cancer has surpassed leukemia as the leading cause of cancer death among children and adolescents.
Journal ArticleDOI
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Denise R. Aberle,Amanda M. Adams,Christine D. Berg,William C. Black,Jonathan D. Clapp,Richard M. Fagerstrom,Ilana F. Gareen,Constantine Gatsonis,Pamela M. Marcus,JoRean D. Sicks +9 more
TL;DR: Screening with the use of low-dose CT reduces mortality from lung cancer, as compared with the radiography group, and the rate of death from any cause was reduced.
Journal ArticleDOI
Sex differences in immune responses
Sabra L. Klein,Katie L. Flanagan +1 more
TL;DR: It is emphasized that sex is a biological variable that should be considered in immunological studies and contribute to variations in the incidence of autoimmune diseases and malignancies, susceptibility to infectious diseases and responses to vaccines in males and females.
Journal ArticleDOI
Colorectal cancer statistics, 2020.
Rebecca L. Siegel,Kimberly D. Miller,Ann Goding Sauer,Stacey A. Fedewa,Lynn F. Butterly,Lynn F. Butterly,Joseph C. Anderson,Joseph C. Anderson,Andrea Cercek,Robert A. Smith,Ahmedin Jemal +10 more
TL;DR: Progress against CRC can be accelerated by increasing access to guideline‐recommended screening and high‐quality treatment, particularly among Alaska Natives, and elucidating causes for rising incidence in young and middle‐aged adults.